Explore the Agenda
8:00 am Check-in, Coffee & Light Breakfast
Workshop A
9:00 am Engineering Dual Payload ADCs to Expand Therapeutic Window, Overcome Resistance & Unlock Novel Synergies
This workshop examines the emerging complexity of dual- and multi-payload ADC design, where the promise of enhanced efficacy through mechanistic synergy must be balanced against fundamental constraints in biology, chemistry, and translational predictability. It asks whether combining payloads truly expands the therapeutic window or whether it introduces new layers of variability in exposure, toxicity, and resistance evolution.
- Explore how dual and multi payload ADCs are enabling synergistic mechanisms that outperform traditional combination approaches
- Understand how rational payload pairing strategies can expand addressable patient populations and overcome emerging resistance mechanisms
- Examine the chemistry and translational challenges associated with linker payload synthesis, in vivo evaluation, and optimization of dual payload systems
- Learn how developers are integrating novel payload classes alongside established cytotoxics to revive promising mechanisms and differentiate next generation ADCs
- Assess evolving clinical and preclinical data supporting dual payload approaches and identify where the field is seeing meaningful therapeutic advantage
12:00 pm Lunch Break & Networking
Workshop B
1:00 pm Expanding the ADC Therapeutic Window to Improve Safety, Efficacy, & Clinical Success
This workshop examines one of the central tensions in ADC development, asking how potent is too potent. It explores whether increasing payload potency truly expands the therapeutic window or simply shifts toxicity into new and sometimes less predictable profiles. Through case based discussion, the session will analyze how DAR optimization, site specific conjugation, linker selection and payload characteristics collectively shape safety, efficacy and clinical usability
- Examine how payload permeability, linker stability and intracellular release location collectively determine safety margins and clinical feasibility
- Challenge the assumption that extreme payload potency is always required for ADC success, tracing where this paradigm originated and when it no longer holds
- Discuss trade‑offs between payload potency, off‑target toxicity, dosing flexibility, and clinical tolerability
- Explore practical strategies to balance potency, dosing flexibility and tolerability including mechanism selective payload design and refined conjugation approaches to improve therapeutic index